DC Chemicals · Product datasheet

Monomethyl auristatin E (vedotin) — Datasheet

CAT. NO. DC7021

Product page and current package options

ParameterValue
Chemical Name(S)-N-((3R,4S,5S)-1-((S)-2-((1R,2R)-3-(((1R,2R)-1-Hydroxy-1-phenylpropan-2-yl)amino)-1-methoxy-2-methyl-3-oxopropyl)pyrrolidin-1-yl)-3-methoxy-5-methyl-1-oxohe;[3H]-Vedotin;MMAE;MMAE（Monomethyl Auristain E）;MONOMETHYL AURISTATIN E;Vedotin;N-Methyl-L-valyl
CAS No.474645-27-7
SynonymsMMAE, SGD-1010
FormulaC39H67N5O7
M.Wt717.97859120369
SMILESCN[C@H](C(N[C@H](C(N(C([C@@H](CC(N1CCC[C@H]1[C@@H]([C@H](C(N[C@@H]([C@H](C1C=CC=CC=1)O)C)=O)C)OC)=O)OC)[C@H](CC)C)C)=O)C(C)C)=O)C(C)C
Purity>98%
Storage2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Biological Activity

Monomethyl auristatin E (MMAE) is a synthetic derivative of dolastatin 10 and functions as a potent mitotic inhibitor by inhibiting tubulin polymerization. MMAE is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) to treat several different cancer types.

In Vitro

Monomethyl auristatin E (MMAE) is efficiently released from SGN-35 within CD30+ cancer cells and, due to its membrane permeability, is able to exert cytotoxic activity on bystander cells[1]. MMAE sensitizes colorectal and pancreatic cancer cells to IR in a schedule and dose dependent manner correlating with mitotic arrest. Radiosensitization is evidenced by decreased clonogenic survival and increased DNA double strand breaks in irradiated cells[2].

In Vivo

Monomethyl auristatin E (MMAE) in combination with IR results in tumor growth delay, tumor-targeted ACPP-cRGD-MMAE with IR produces a more robust and significantly prolongs tumor regression in xenograft models[2].

References & source

DC Chemicals original product information

Published experimental findings depend on the model and assay conditions. They do not guarantee equivalent performance in every application. For laboratory research use only.

Cart

Request quotation